天康生物
(002100)
| 流通市值：103.21亿 | | | 总市值：103.21亿 |
| 流通股本：13.65亿 | | | 总股本：13.65亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 8,325,389,560.74 | 3,916,826,741.94 | 16,981,074,699.26 | 13,610,370,203.12 |
| 营业收入 | 8,325,389,560.74 | 3,916,826,741.94 | 16,981,074,699.26 | 13,610,370,203.12 |
| 二、营业总成本 | 8,784,305,956.8 | 4,059,490,050.25 | 16,576,749,906.39 | 13,098,483,091.04 |
| 营业成本 | 8,206,630,230.08 | 3,765,570,499.79 | 15,306,380,317.77 | 12,129,821,528.94 |
| 税金及附加 | 28,438,998.81 | 14,040,567.08 | 50,070,980.94 | 35,746,600.1 |
| 销售费用 | 174,180,446.63 | 91,711,270.95 | 381,303,993.17 | 294,881,912.31 |
| 管理费用 | 234,261,436.59 | 115,992,429.52 | 517,135,979.19 | 370,467,316.92 |
| 研发费用 | 76,712,916.05 | 37,212,089.08 | 183,506,429.54 | 164,593,119.84 |
| 财务费用 | 64,081,928.64 | 34,963,193.83 | 138,352,205.78 | 102,972,612.94 |
| 其中:利息费用 | 64,255,731.16 | 35,202,406.67 | 159,995,645.74 | 112,841,990.57 |
| 其中:利息收入 | 4,124,597 | 4,097,384.69 | 24,220,746.08 | 18,852,558.07 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,712,743.67 | 707,711.39 | 807,450.93 | 354,952.96 |
| 加:投资收益 | 3,244,415.45 | 110,795.09 | 33,827,765.77 | -9,492,630.37 |
| 资产处置收益 | 299,952.37 | -603,747.52 | 587,072.68 | -192,326.85 |
| 资产减值损失(新) | -4,786,473.14 | -3,364,170.8 | -46,098,106.21 | -4,094,463.56 |
| 信用减值损失(新) | -39,257,194.51 | -20,238,406.54 | -131,543,845.6 | -38,433,637.16 |
| 其他收益 | 26,536,719.48 | 11,061,763.39 | 60,304,441.18 | 41,972,572.82 |
| 四、营业利润 | -471,166,232.74 | -154,989,363.3 | 322,209,571.62 | 502,001,579.92 |
| 加:营业外收入 | 3,974,108.58 | 946,795.55 | 44,585,704.31 | 41,809,484.34 |
| 减:营业外支出 | 21,719,055.39 | 9,645,739.46 | 38,685,876.71 | 28,417,541.11 |
| 五、利润总额 | -488,911,179.55 | -163,688,307.21 | 328,109,399.22 | 515,393,523.15 |
| 减:所得税费用 | 5,289,150.72 | 8,819,858.75 | 27,801,208.75 | 10,528,434.89 |
| 六、净利润 | -494,200,330.27 | -172,508,165.96 | 300,308,190.47 | 504,865,088.26 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -494,200,330.27 | -172,508,165.96 | 300,308,190.47 | 504,865,088.26 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -441,468,238.37 | -163,281,842.86 | 210,634,875.2 | 411,749,486.05 |
| 少数股东损益 | -52,732,091.9 | -9,226,323.1 | 89,673,315.27 | 93,115,602.21 |
| 扣除非经常损益后的净利润 | -445,686,964.32 | -162,022,821.05 | 150,924,111.22 | 381,756,447.68 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.32 | -0.12 | 0.15 | 0.3 |
| (二)稀释每股收益 | -0.32 | -0.12 | 0.15 | 0.3 |
| 八、其他综合收益 | -52,668,595.28 | 77,495,593.39 | 13,946,007.7 | 42,755,441.21 |
| 归属于母公司股东的其他综合收益 | -51,162,244.91 | 80,973,638.4 | 12,595,684.88 | 42,732,831.34 |
| 九、综合收益总额 | -546,868,925.55 | -95,012,572.57 | 314,254,198.17 | 547,620,529.47 |
| 归属于母公司股东的综合收益总额 | -492,630,483.28 | -82,308,204.46 | 223,230,560.08 | 454,482,317.39 |
| 归属于少数股东的综合收益总额 | -54,238,442.27 | -12,704,368.11 | 91,023,638.09 | 93,138,212.08 |
| 公告日期 | 2026-08-27 | 2026-04-30 | 2026-04-29 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |